Summary for 6MX8
Entry DOI | 10.2210/pdb6mx8/pdb |
Descriptor | ALK tyrosine kinase receptor, 5-chloro-N~4~-[2-(dimethylphosphoryl)phenyl]-N~2~-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine (3 entities in total) |
Functional Keywords | alk kinase, brigatinib, tyrosine kinase, transferase |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 35073.80 |
Authors | Dougan, D.R.,Zhou, T. (deposition date: 2018-10-30, release date: 2018-12-12, Last modification date: 2024-03-13) |
Primary citation | Huang, W.S.,Liu, S.,Zou, D.,Thomas, M.,Wang, Y.,Zhou, T.,Romero, J.,Kohlmann, A.,Li, F.,Qi, J.,Cai, L.,Dwight, T.A.,Xu, Y.,Xu, R.,Dodd, R.,Toms, A.,Parillon, L.,Lu, X.,Anjum, R.,Zhang, S.,Wang, F.,Keats, J.,Wardwell, S.D.,Ning, Y.,Xu, Q.,Moran, L.E.,Mohemmad, Q.K.,Jang, H.G.,Clackson, T.,Narasimhan, N.I.,Rivera, V.M.,Zhu, X.,Dalgarno, D.,Shakespeare, W.C. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J. Med. Chem., 59:4948-4964, 2016 Cited by PubMed: 27144831DOI: 10.1021/acs.jmedchem.6b00306 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.96 Å) |
Structure validation
Download full validation report